The Effects of modified-release fampridine on upper limb impairment in multiple sclerosis

被引：0
|
作者：
Simpson, M. [1 ]
Churilov, L. [2 ]
Bardsley, B. [1 ]
Heriot, E. [1 ]
Dimovitis, J. [1 ]
Carey, L. [3 ]
Macdonell, R. [1 ]
机构：
[1] Univ Melbourne, Austin Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Stat, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1294
引用
收藏
页码：685 / 685
页数：1
相关论文
共 50 条
  • [31] Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis
    Mathiesen, Henrik K.
    Sorensen, Per S.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 1309 - 1317
  • [32] Prolonged clinical effects in modified-release amitriptyline poisoning
    O'Connor, N
    Greene, S
    Dargan, P
    Wyncoll, D
    Jones, A
    CLINICAL TOXICOLOGY, 2006, 44 (01) : 77 - 80
  • [33] Quantifying upper-limb motor impairment in people with multiple sclerosis: A physiological profiling approach
    Ingram, Lewis A.
    Butler, Annie A.
    Brodie, Matthew A.
    Hoang, Phu
    Gandevia, Simon C.
    Lord, Stephen R.
    ANNALS OF PHYSICAL AND REHABILITATION MEDICINE, 2022, 65 (05)
  • [34] QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE 10 MG TABLETS FOR WALKING IMPAIRMENT
    Liu, Y.
    McNeill, M.
    Lee, A.
    Zhong, J.
    Mehta, L. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A402
  • [35] The effects of extended release fampridine on fatigue in patients with multiple sclerosis (ms): a systematci review and meta-analysis
    Ghajarzadeh, Mahsa
    rastkar, mohsen
    Nourbakhsh, Bardia
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1026 - 1026
  • [36] A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis
    McNicholas, N.
    O'Connell, K.
    Yap, S. M.
    O'Boyle, G.
    Cox, S.
    Sharma, D.
    Jordan, S.
    Buckley, L.
    Muldowney, C.
    Donnelly, C.
    Sheik, A.
    Walsh, C.
    Tubridy, N.
    Hutchinson, M.
    McGuigan, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 466 - 467
  • [37] Multiple sclerosis Slow-release Fampridine improved walking ability by every third
    Schindler, Birgit
    PSYCHOPHARMAKOTHERAPIE, 2009, 16 (05): : 221 - 222
  • [38] Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis
    Fernandez, Oscar
    Berger, Thomas
    Hartung, Hans-Peter
    Putzki, Norman
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (06) : 649 - 665
  • [39] Patient reported symptoms associated with activities of daily living in upper limb impairment for people with multiple sclerosis
    Street, T.
    Swain, I.
    Taylor, P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 129 - 130
  • [40] Sustained-release fampridine for multiple sclerosis (vol 18, pg 1013, 2009)
    Bever, Christopher T., Jr.
    Judge, Susan Iv
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) : 1241 - 1241
12345